Autolus Therapeutics (NASDAQ:AUTL) Hits New 1-Year Low – Here’s What Happened

Autolus Therapeutics plc (NASDAQ:AUTL)’s share price reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $1.92 and last traded at $1.97, with a volume of 124566 shares traded. The stock had previously closed at $2.03.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Needham & Company LLC restated a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research report on Monday, January 13th. The Goldman Sachs Group raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the company from $7.00 to $7.60 in a research note on Monday, November 18th. Finally, Redburn Atlantic upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective on the stock in a report on Friday, November 15th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $10.40.

Autolus Therapeutics Trading Down 3.2 %

The firm’s 50 day simple moving average is $2.42 and its 200-day simple moving average is $3.36. The stock has a market capitalization of $522.87 million, a price-to-earnings ratio of -1.62 and a beta of 2.02.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period last year, the company posted ($0.26) earnings per share. As a group, equities research analysts predict that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Institutional Trading of Autolus Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Millennium Management LLC increased its holdings in shares of Autolus Therapeutics by 113.7% during the second quarter. Millennium Management LLC now owns 813,031 shares of the company’s stock worth $2,829,000 after purchasing an additional 432,503 shares during the period. Exchange Traded Concepts LLC increased its holdings in Autolus Therapeutics by 9.8% in the 3rd quarter. Exchange Traded Concepts LLC now owns 41,866 shares of the company’s stock worth $152,000 after purchasing an additional 3,740 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Autolus Therapeutics by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 38,393 shares of the company’s stock worth $139,000 after buying an additional 14,959 shares during the period. Privium Fund Management B.V. grew its stake in shares of Autolus Therapeutics by 15.6% in the third quarter. Privium Fund Management B.V. now owns 185,639 shares of the company’s stock worth $674,000 after purchasing an additional 25,000 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new stake in shares of Autolus Therapeutics in the 3rd quarter valued at about $1,082,000. Institutional investors and hedge funds own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.